Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: J Nutr Biochem. 2011 Aug 17;23(8):915–923. doi: 10.1016/j.jnutbio.2011.04.017

Fig. 5.

Fig. 5

ERK and PKC mediate C/EBPβ and damnacanthal-induced NAG-1 expression. (A) HCT-116 cells were treated with DMSO, 0.1, 1, 10 and 20 μM of Dam for 24 h, and Western blot was performed for C/EBPβ and actin as described in Materials and methods. (B) HCT-116 cells were pretreated with different kinase inhibitors (U0126, 5 μM; RO318220, 2.5 μM; AG490, 50 μM; SB203580, 15 μM; SP 600125, 30 μM) for 30 min and treated with 20 μM of Dam for 24 h. Western blot was performed for C/EBPβ, NAG-1 and actin. (C) The NAG-1 promoter (pNAG-1-133/+41) and pRL-null vector were transfected for 24 h, as described in Materials and methods, pretreated with U0126 (1 or 5 μM) and then treated with DMSO or 20 μM of Dam for 24 h. The y-axis shows fold induction over DMSO-treated cells. *P<0.05 versus Dam 20 μM-treated cells. (D) HCT-116 cells were transfected with pcDNA 3.1 empty vector, ERK2 wild type or a dominant negative ERK2 as described in Materials and methods, and treated with DMSO or 10 μM of Dam for 24 h. Western blot was performed for FLAG, C/EBPβ , NAG-1 and actin.